Improved absorption of meloxicam via salt formation with ethanolamines

被引:67
作者
Han, Hyo-Kyung [1 ]
Choi, Hoo-Kyun [1 ]
机构
[1] Chosun Univ, Coll Pharm, Kwangju 501759, South Korea
关键词
meloxicam; ethanolamine salts; pharmacokinetics; dissolution rate; rats;
D O I
10.1016/j.ejpb.2006.07.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The present study aimed to investigate the effect of ethanolamine salt formation on the dissolution as well as in vivo pharmacokinetics of meloxicam. Three meloxicam-ethanolamine salts were prepared and their in vitro dissolution profiles were examined at pH 1.2 and 6.8. The pharmacokinetic profiles of meloxicam following an oral administration of meloxicam or its ethanolamine salts were also evaluated in rats. The dissolution rates of meloxicam and its ethanolamine salts were similarly slow at pH 1.2, however, at pH 6.8, ethanolamine salt formation significantly enhanced the dissolution rate of meloxicam. Meloxicam diethanolamine salt exhibited the highest dissolution rate at pH 6.8. The faster dissolution of meloxicam via ethanolamine salt formation at pH 6.8 appeared to be correlated well with more rapid absorption of meloxicam in rats. T-max of meloxicam was significantly (p < 0.05) shortened following an oral administration of ethanolamine salts. Furthermore, ethanolamine salts exhibited a trend toward the increase in AUC(0-4) (initial exposure), while the overall exposure (AUC(0-24)) was similar between meloxicam and its salts. In conclusion, the ethanolamine salts of meloxicam, particularly diethanolamine salt of meloxicam, facilitated the rapid absorption of meloxicam while maintaining the prolonged exposure and may be used for the earlier onset of action for meloxicam. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:99 / 103
页数:5
相关论文
共 20 条
[1]  
Busch U, 1998, DRUG METAB DISPOS, V26, P576
[2]   Clinical pharmacokinetics of meloxicam - A cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug [J].
Davies, NM ;
Skjodt, NM .
CLINICAL PHARMACOKINETICS, 1999, 36 (02) :115-126
[3]  
Engelhardt G, 1996, BRIT J RHEUMATOL, V35, P4
[4]  
Euller-Ziegler L, 2001, INFLAMM RES, V50, pS5
[5]   Tablet formulation containing meloxicam and β-cyclodextrin:: Mechanical characterization and Bioavailability evaluation -: art. no. 59 [J].
Ghorab, MM ;
Abdel-Salam, HM ;
El-Sayad, MA ;
Mekhel, MM .
AAPS PHARMSCITECH, 2004, 5 (04)
[6]   Preparation and evaluation of solid dispersion of meloxicam with skimmed milk [J].
Gurusamy, S ;
Kumar, V ;
Mishra, DN .
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2006, 126 (02) :93-97
[7]   Enhanced bioavailability of piroxicam via salt formation with ethanolamines [J].
Gwak, HS ;
Choi, JS ;
Choi, HK .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 297 (1-2) :156-161
[8]  
Hanft G, 2001, INFLAMM RES, V50, pS35
[9]   Ion pair skin transport of a zwitterionic drug, cephalexin [J].
Hatanaka, T ;
Kamon, T ;
Morigaki, S ;
Katayama, K ;
Koizumi, T .
JOURNAL OF CONTROLLED RELEASE, 2000, 66 (01) :63-71
[10]  
KI HM, 2006, IN PRESS ARCH PHARM